Intravenous Pegloticase Market Trends

Growth Drivers

• High Volume of Alcohol Consumption: According to data from the World Health Organization in 2018 approximately the worldwide consumption of alcohol was 6.2 liters of alcohol per person 15 years and older. An estimate of unrecorded consumption accounts for 26% of the worldwide total consumption. This high rate of alcohol consumption has been linked to a higher prevalence of gout, as alcohol can raise uric acid levels in the body which is a key factor in gout development. Consequently, as alcohol patterns evolve, with more individuals engaging in heavy or regular drinking, the incidence of gout may rise, driving the demand for treatment like intravenous pegloticase to manage severe cases.
• High Treatment Efficacy of Intravenous Pegloticase: Intravenous Pegloticase has demonstrated high efficacy in reducing serum uric acid levels and resolving symptoms of severe gout, even in patients with treatment-resistant disease. Its ability to rapidly break down uric acid crystals and maintain low uric acid crystals and maintain low uric acid levels over an extended period makes it a compelling treatment option for individuals who have not responded well to conventional therapies. The proven effectiveness contributes to the growing demand for the adoption of intravenous pegloticase in the management of severe gout, further driving intravenous pegloticase market growth.
• Limited Treatment Options for Gout: Managing gout can pose challenges, and numerous patients fail to optimal symptom control using traditional treatments like nonsteroidal anti-inflammatory drugs (NSAIDs) such as meloxicam, ibuprofen, naproxen, and indomethacin. Intravenous pegloticase stands out as a crucial treatment choice. Its unique mechanism offers hope to patients who have failed to respond to conventional treatment. As a result, the lack of satisfactory alternatives drives demand for intravenous pegloticase, positioning it as a vital solution for the management of chronic and refectory gout, thus contributing to intravenous pegloticase market growth.

Challenges

• High cost: Intravenous pegloticase can cost significantly more than other conventional gout treatments, limiting access for lower-income households. This dissuades patients from seeking or continuing treatment leading to lower adoption rates. Thus, resulting in reduced market penetration and slower revenue growth for the market
• Side effects such as anaphylaxis which is associated with the use of intravenous pegloticase are expected to cause challenges for the market growth.
• Lack of awareness among the patients can let the condition remain undiagnosed and untreated in many cases which can hinder the intravenous pegloticase market growth.